阿托伐他汀联合曲美他嗪治疗慢性心力衰竭的效果观察

Effects observation of atorvastatin combined with trimetazidine in treat-ing chronic heart failure

目的观察阿托伐他汀联合曲美他嗪治疗慢性心力衰竭的临床疗效。方法选择2015年1-6月于我院心内科就诊的慢性心竭患者54例，将其随机分为对照组和观察组，每组27例。两组均在常规抗心力衰竭治疗基础上，同时予以阿托伐他汀治疗，观察组联合应用曲美他嗪，6个月后比较两组患者的治疗有效率、心功能监测指标（心率、左心室射血分数、6min步行距离和血浆心房钠尿肽浓度）和不良反应情况。结果治疗6个月后，对照组的总有效率为85．2％，观察组的总有效率为96．3％，观察组疗效明显优于对照组，差异有统计学意义（P〈0．05）。两组的心率、左心室射血分数、6min步行距离和血浆心房钠尿肽浓度均较用药前改善，且观察组改善程度明显优于对照组（P〈0．05）。治疗6个月过程中，两组均未出现明显的不良反应。结论阿托伐他汀联合曲美他嗪在治疗慢性心力衰竭方面较单用阿托伐他汀有更好的疗效，有广阔的临床应用前景。

Objective To observe the clinical effects of atorvastatin combined with trimetazidine in treating chronic heart failure.Methods 54 chronic heart failure patients from January to June 2015 of cardiology department in our hos- pital were selected.Patients were randomly divided into control group and observation group,and each group was 27 cases.All patients in two groups were given atorvastatin on the basis of routine anti-heart failure treatment.Patients in observation group were further given trimetazidine.After treatment for 6 months,the treatment effective rate,cardiac function monitoring indicators including heart rate,left ventricular ejection fraction,6-minute walk distance and plasma atrial natriuretic peptide concentration,adverse effects in two groups were compared.Results After treatment for 6 months,the total effective rate in control group and observation group was respectively 85.2% and 96.3%,the total effec- tive rate in observation group was obvious better than that of control group and the difference was statistical signifi- cance（P〈0.05）.The heart rate,left ventricular ejection fraction,6-minute walk distance and plasma atrial natriuretic pep- tide concentration in two groups was improved than before treatment respectively,and the improvement degree in obser- vation group was obvious better than that of control group （P〈0.05）.Any adverse effects appeared in two groups during the 6 months treatment.Conclusion The effects of atorvastatin combined with trimetazidine in treating chronic heart failure is better than single uses of atorvastatin and which with wide clinical application prospect.